FDA warns about fraudulent and unapproved GLP-1 products
The FDA has warned about fraudulent and unapproved compounded GLP-1 products, including false labels and dosing-error adverse events.
The FDA has warned about fraudulent and unapproved compounded GLP-1 products, including false labels and dosing-error adverse events.

The FDA has published concerns about unapproved GLP-1 drugs used for weight loss, including compounded semaglutide and tirzepatide. The agency says it is aware of fraudulent compounded products carrying false labels — in some cases naming pharmacies that do not exist, or that did not make the product.
The FDA reports it has received adverse event reports linked to these products, some of them requiring hospitalization, and ties these to dosing errors. It also clarifies a point that is easy to miss: salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients from the approved drugs. A label that names a salt form is not naming the same molecule. The agency advises checking labels for warning signs such as misspellings or wrong addresses.
Reporting data adds scale. Becker's Hospital Review reported that as of May 31, 2026, the FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, with the caveat that adverse events are believed to be underreported.
The lesson for a buyer is that "compounded" and "approved" are not the same, a salt form is not the same molecule, and a label can be fabricated. The defense is the same as elsewhere: an independent certificate that reports identity (including the exact molecule, not a salt variant), content, and endotoxin, with a lot number and a way to verify the report. A COA that cannot be verified, or that lacks a lot, is one of the warning signs the FDA is effectively describing here.
FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Becker's Hospital Review (May 31, 2026).
Regulator2023In September 2023 the FDA placed BPC-157 on its list of bulk drug substances that may present significant safety risks for compounding.
Explainer2024What 'research use only' actually means, and how the FDA's position on peptides and unapproved GLP-1s frames it.